Not needed after all, WTO drops the COVID-19 TRIPS waiver – The Pharma Letter

A bold move to rip up intellectual property protections for COVID-19 vaccines appears to have been quietly dropped, after the World Trade Organization (WTO) opted not to extend the measure.

At the height of the COVID-19 pandemic, many commentators argued for a radical change to global licensing rules, compelled by the urgency of the situation and the need to broaden access to newly-available vaccines.

This led to the so-called Trade-Related Aspects

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

Continued here:

Not needed after all, WTO drops the COVID-19 TRIPS waiver - The Pharma Letter